// App-Quantinova.ai

: Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles

Researchers

Presenter

  • Cedric Van Holsbeke

Principal Investigators

  • Jan De Backer

  • Wim Vos

  • Jonathan Marshall

Medical Centers

  • FLUIDDA NV, Kontich, Belgium,

  • Mundipharma International Ltd., Market Access, Cambridge, United Kingdom

Locations

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Bone Morphogenetic Protein 1

Drug/Treatment

  • budesonide + formoterol fuma

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Mundipharma Deutschland GmbH & Co. KG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved